TGFB1 and neoplasm: Approaches such as modifying the tumor microenvironment through anti-TGF-β or anti-CD73 antibodies, activating innate immunity with TLR9 agonists, or employing combination regimens involving checkpoint inhibitors and targeted therapies show potential.